Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Fda crawled date : 2022 - 01 - 18 save search
Surgalign Receives FDA Clearance for HOLO Portal™ System, the World’s First AI-driven AR Guidance System for Spine Surgery
Published: 2022-01-18 (Crawled : 16:00) - biospace.com/
SRGA | $0.1829 -50.36% 8.7M
|
Health Technology
|
| O: 20.57%
H: 5.88%
C: -21.35%
fda clearance system fda clearance spine
Dyne Therapeutics Announces FDA Clinical Hold on IND Application for DYNE-251 in Duchenne Muscular Dystrophy
Published: 2022-01-18 (Crawled : 15:30) - biospace.com/
DYN | $25.36 -0.31% 130K
|
Health Technology
|
| O: -15.82%
H: 6.78%
C: 3.84%
dyne-251 clinical hold fda muscular dystrophy application therapeutics duchenne
NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology
Published: 2022-01-18 (Crawled : 15:30) - biospace.com/
NURO A | $4.439 4.1K
|
Health Technology
|
| O: 23.17%
H: 22.28%
C: 5.12%
treatment fda device technology therapy designation
Aditxt Submits Two Requests for Emergency Use Authorization to FDA for AditxtScore™ for COVID-19 Tests Which Measure the Quantity and Quality of Antibodies Against COVID-19 and its Variants Including Omicron
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
ADTX | $2.27 23K
|
Health Technology
|
| O: 2.73%
H: 1.66%
C: -6.11%
covid-19 fda covid authorization test merge antibody emergency use authorization
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-101 in Development for the First-Line Treatment of Advanced HER2/neu Positive Gastric and Gastroesophageal Junction Cancers
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
CELU | News F | $3.25 1.25% 8.3K
|
|
| O: 4.83%
H: 0.0%
C: -12.21%
cynk-101 fast track designation treatment fda fast track cel positive therapy cancer her2- her2
PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to Support Chronic Cutaneous Ulcer Indication
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
PTE | $0.241 -0.82% -6.68% 0
|
Consumer Durables
|
| O: 3.81%
H: 11.07%
C: -3.92%
skinte fda fda approval skin approval phase 3
HOOKIPA Announces First Patient Enrolled in Phase 2 Trial Evaluating HB-200 and Pembrolizumab for Treatment of Head and Neck Cancer and Reports FDA’s Fast Track Designation
Published: 2022-01-18 (Crawled : 15:00) - biospace.com/
HOOK | $0.739 -3.4% 8.4M
|
Health Technology
|
| O: 0.0%
H: 2.44%
C: -1.46%
hb-200 fast track designation treatment fda phase 2 fast track trial report cancer enroll designation
BioLineRx Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patients
Published: 2022-01-18 (Crawled : 14:00) - biospace.com/
BLRX | $0.591 -7.19% 430K
|
Health Technology
|
| O: 7.61%
H: 3.3%
C: 2.83%
fda cel stem cell
Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis- Positive feedback from FDA to initiate Phase 3 trial of atacicept in patients with LN -
Published: 2022-01-18 (Crawled : 13:30) - biospace.com/
VERA | $38.96 -1.42% 150K
|
Professional, Scientific, and T...
|
| O: -8.03%
H: 8.58%
C: 2.84%
fda trial therapeutics positive phase 3 lupus
Antares Pharma Receives FDA Fast Track Designation for ATRS-1902 for Adrenal Crisis Rescue
Published: 2022-01-18 (Crawled : 13:00) - biospace.com/
ATRS | $5.59 0.0%
|
Health Technology
|
| O: 0.9%
H: 0.0%
C: -4.24%
atrs-1902 fast track designation fda fast track renal fda fast track designation pharma
CASI PHARMACEUTICALS ANNOUNCES CNCT19 (CD19 CAR-T) GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA
Published: 2022-01-18 (Crawled : 13:00) - biospace.com/
CASI | $2.51 3.3K
|
Health Technology
|
| O: -5.62%
H: 3.48%
C: -6.69%
cnct19 fda als car-t drug granted orphan drug grant designation
Celcuity Receives FDA Fast Track Designation for Gedatolisib in HR+ / HER2- Metastatic Breast Cancer and Provides Corporate Update
Published: 2022-01-18 (Crawled : 13:00) - biospace.com/
CELC | $16.975 -1.54% 26K
|
Commercial Services
|
| O: -2.16%
H: 7.88%
C: 2.12%
fast track designation fda fast track cel fda fast track cancer breast cancer designation her2- her2 metastatic breast cancer
bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)
Published: 2022-01-18 (Crawled : 12:30) - biospace.com/
BLUE | $0.9227 -4.94% 4.6M
|
Health Technology
|
| O: -3.19%
H: 1.0%
C: -6.94%
fda cel
ADMA BioCenters Receives FDA Approval for its Fourth Plasma Collection Center Located in Goose Creek, SC
Published: 2022-01-18 (Crawled : 12:00) - admabiologics.com
ADMA 4 | $6.455 -1.3% 570K
|
Health Technology
|
| O: 7.34%
H: 0.0%
C: 0.0%
fda fda approval approval
Gainers vs Losers
| 55% | 45% |
Top 10 Gainers
CSSE 4 | $0.3499 129.74% 150M
|
Consumer Services
CZOO | $11.04 121.24% 9.6M
|
BOF | $2.05 75.21% 78M
|
AMST | $3.2 60.0% 63M
|
Technology Services
WIMI | $1.05 44.75% 13M
|
Technology Services
LICN | $0.7885 40.8% 11M
|
TROO | $1.51 38.53% 5.6M
|
Manufacturing
MULN | News | $3.7 35.53% 6.4M
|
Information
RILY | $27.91 28.5% 8.9M
|
Finance
WHLM | $6.43 26.58% 580K
|
Commercial Services
Your saved searches
Save your searches and get alerts when important news are released.